Concordant loss of all 3 commonly used melanocytic markers (ie, S-100, HMB-45, and Melan-A) in a primary malignant melanoma with expression of the same in the metastatic lesion is very rare. To the best of the authors’ knowledge, they documented the second case of this unusual and rare phenomenon.
Banerjee SS, Harris M.Morphological and immunophenotypic variations in malignant melanoma. Histopathology. 2000;36:387-402.
2.
Banerjee SS, Eyden B.Divergent differentiation in malignant melanomas: a review. Histopathology. 2008;52:119-129.
3.
Shinohara M. , Deubner H., Argenyi ZBS100, HMB-45, and Melan-A negative primary melanoma. Dermatol Online J.2009;15(9):7.
4.
Argenyi ZB, Cain C., Bromley C., et al. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol . 1994;16:233-240.
5.
Kim YC, Lee MG, Choe SW, Lee MC, Chung HG, Cho S.Acral lentiginous melanoma: an immunohistochemical study of 20 cases. Int J Dermatol. 2003;42:123-129.
Bilalovic N. , Sandstad B., Golouh R., Nesland JM, Selak I., Torlakovic EECD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol. 2004;17:1251-1258.
8.
Fidler IJ, Hart IRBiologic diversity in metastatic neoplasms: origins and implications. Science. 1982;217:998-1003.
9.
Mangini J., Li N., Bhawan J.Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am J Dermatopathol. 2002;24:270-281.
10.
Plaza JA, Suster D., Perez-Montiel D.Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique . Appl Immunohistochem Mol Morphol. 2007;15:412-425.
